Defining the transcriptional and cellular landscape of type 1 diabetes in the NOD mouse

Javier A. Carrero  
*Washington University School of Medicine in St. Louis*

Boris Calderon  
*Washington University School of Medicine in St. Louis*

Fadi Towfic  
*Immuneering Corporation, Cambridge, Massachusetts*

Maxim N. Artyomov  
*Washington University School of Medicine in St. Louis*

Emil R. Unanue  
*Washington University School of Medicine in St. Louis*

Follow this and additional works at: [https://digitalcommons.wustl.edu/open_access_pubs](https://digitalcommons.wustl.edu/open_access_pubs)

**Recommended Citation**  
Carrero, Javier A.; Calderon, Boris; Towfic, Fadi; Artyomov, Maxim N.; and Unanue, Emil R., "Defining the transcriptional and cellular landscape of type 1 diabetes in the NOD mouse." PLoS One. 8,3. e59701. (2013).  
[https://digitalcommons.wustl.edu/open_access_pubs/1366](https://digitalcommons.wustl.edu/open_access_pubs/1366)

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Defining the Transcriptional and Cellular Landscape of Type 1 Diabetes in the NOD Mouse

Javier A. Carrero1*, Boris Calderon1, Fadi Towfic2, Maxim N. Artyomov1, Emil R. Unanue1

1 Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America, 2Immuneering Corporation, Cambridge, Massachusetts, United States of America

Abstract

Our ability to successfully intervene in disease processes is dependent on definitive diagnosis. In the case of autoimmune disease, this is particularly challenging because progression of disease is lengthy and multifactorial. Here we show the first chronological compendium of transcriptional and cellular signatures of diabetes in the non-obese diabetic mouse. Our data relates the immunological environment of the islets of Langerhans with the transcriptional profile at discrete times. Based on these data, we have parsed diabetes into several discrete phases. First, there is a type I interferon signature that precedes T cell activation. Second, there is synchronous infiltration of all immunological cellular subsets and a period of control. Finally, there is the killing phase of the diabetogenic process that is correlated with an NF-kB signature. Our data provides a framework for future examination of autoimmune diabetes and its disease progression markers.

Introduction

T1D is a T-cell dependent autoimmunity directed against the β-cells of the pancreatic islets of Langerhans, a process where autoreactive CD4+ T cells are directed to antigens of the β-cells[1–4]. The most important genetic determinant of T1D incidence in both humans and mice is the major histocompatibility complex (MHC) [5,6]. Despite the strong genetic component of predisposition to disease, concordance between monozygotic twins is approximately 50% [1,7]. Beside the interplay of genes and environment in the induction of T1D, there are complex interactions between different immune cell systems that determine the outcome of disease [8].

Transcriptional profiling permits an unbiased examination on a genome-wide scale. Thus, it is a powerful tool for analyzing complex problems like T1D. Examination of islets of Langerhans, islet infiltrating leukocytes, and pancreatic lymph nodes has been conducted following several genetic, biological or chemical manipulations[9–14]. Several important findings have come from these types of studies. Global expression patterns distinguish destructive versus innocuous innocuous responses of islet infiltrating leukocytes [9]. Chemically induced diabetes led to upregulation of inflammatory genes with an interferon-γ (IFN-γ) signature in islets of Langerhans [11]. The balance between pancreatic destruction and repair was detected by examining inflammatory signatures, culminating in the destruction of the islet β-cells [13]. Type I interferon inducible genes were detected in pancreatic lymph node CD4+ T cells isolated from TCR transgenic mice [14]. Transfer of diabetogenic T cells from TCR transgenic mice induced an interferon signature that correlated with amplitification of the autoimmune process [12]. Finally, the genetic programs that led to development of endocrine pancreas were examined using global transcriptional analysis [10]. Despite these many studies, a coherent view of the disease development and corresponding sequence of inflammatory and developmental events in the context of the spontaneous diabetes is lacking to this date.

A challenge of examining an inflamed islet of Langerhans is the diversity of cell types in the sample and the ability to reliably detect changes in levels of expression. Technological improvements in automation, computation, and reduced cost have allowed an expansion of reliable data gathering, annotation, and distillation using microarray technology. The advent of carefully curated resources such as the Immunological Genome Project provide a framework for identifying genes related to specific cell types [15]. The increase in publicly available and user-friendly resources for microarray data analysis also permits reproducible examination of larger data sets [16]. We have leveraged the power of these available resources to generate a dataset identifying the key signatures of progression of T1D in NOD mice.

Here we present the first chronological examination of the transcriptional landscape of T1D progression in the NOD mouse from 2 wks of age until diabetes (~20–30 wks). Several striking results were obtained from the dataset. First, infiltrating myeloid cells begin to populate the islets of Langerhans as early as 4 wks of age. This occurred at a time where the islet was still developing, as determined by signatures of cell cycle and development. Next, a type I interferon signature was detected between 4 and 6 wks of age. This is followed by infiltration of islets by all major leukocyte subsets and T cell activation at 8–12 wks of age. Following full immunological activation, there was a progressive enhancement of inflammatory signatures, culminating in the destruction of the islet β-cells.
of Langerhans. This data and its analysis provide a framework for the study of islets of Langerhans and inflammatory responses during the progression of T1D.

Results

Examination of Islets of Langerhans Reveals a Progressive Entry of Leukocytes Subsets Throughout Diabetogenesis

Islets of Langerhans were isolated, purified, and then examined by fluorescence microscopy and flow cytometry at ages ranging from 2 wks up to newly diabetic. Our goal was to identify changes in leukocyte infiltration, changes in adhesion molecules, and immunoglobulin (Ig) deposition on β-cells (Fig. 1).

At 2 wks of age, islets showed no signs of pathology and no detectable lymphocytes. The earliest time point where lymphocytes were identified inside islets occurred at 4 wks of age. CD4+ T cells were found in 10% of the islets in close apposition to the islet resident CD11c+ cells (Fig. 1A–B). The resident CD11c+CD45+ cells are the intra-islet myeloid cell found in all strains of mice (reviewed in [17]). CD8+ T cells and B cells were rarely identified. In control mice, lymphocytes were not detected inside the islets, only an occasional one was found inside the blood vessels (see below for control information). In 4 wk old NOD mice, the islet distribution of the adhesion molecules ICAM-1 and VCAM-1 showed the profile of a non-inflamed state [12]. ICAM-1 was only found weakly expressed in the endothelium and VCAM-1 was absent (Fig. 1B).

In 6 wk old NOD mice, CD4+ T cells were found in ~1/3rd of the islets, at a median of 3 cells per islet, and always contacting the islet CD11c+ cells (the number ranged from ~1 to 55 leukocytes per islet; Fig. 1B–C). Low numbers of CD8+ T cells also were found while B cells represented a minor component (Fig. 1C). At about this time, many of the intra-islet vessels had higher ICAM-1 expression throughout most of the vessel wall, and about 10% showed VCAM-1 expression (Fig. 1B). These changes in adhesion molecules have been related to the entrance of diabetogenic T cells [12,18]. IgG deposition was found on the β-cells in many of the islets (Fig. 1B). The islets of normal mice never showed deposition of IgG suggesting the presence of NOD-specific autoantibodies.

Major islet changes were found at 8 wks of age. The total number of leukocytes rose ~7-fold, from ~2.7% to 18% of the total islet cellularity (Fig. 1C). CD4+ T cells and CD8+ T cells were found in about half of the islets but B cells only in a limited number, about 10% (Fig. 1B). There was also an increase in the number of CD11c+ cells at this stage (Fig. 1C). We found increased expression of ICAM-1, even on the β-cells, VCAM-1 expression on the vessels, and IgG deposition on the β-cells (Fig. 1B). At 12 wks of age, peri-insulitis, a leukocytic lesion on the pole of the islets, was evident in some islets (Fig. 1A). By 18 wks, islets were heavily infiltrated making quantification difficult (Fig. 1).
Thus, between 4–6 wks the islets of Langerhans showed the first signs of pathology with the entrance of T cells and signs of islet reactivity. Starting at ~3 wks there was a progressive infiltration of all major leukocyte subsets and signs of inflammatory marker expression. The same biological replicates that were interrogated by microscopy were analyzed for their transcriptional expression profiles as detailed below.

**Assembling the Compendium of Transcriptional Profiles in the Context of Islet/Diabetes Development**

To perform chronological analysis of the transcriptional profile, the NOD strain was compared with several control strains. Islet RNA was extracted from 3–6 replicates for each of seven time points along the lifetime of NOD mice (2, 4, 6, 8, 12, 18 wks and up to diabetics at ~20 wks) and compared to 6 replicates of 3 control strains. NOD, Rag1−/− mice at 2 and 6 wks of age were used as a control because they lack the adaptive arm of the immune response, but are otherwise genetically identical to NOD, allowing us to trace non-immune developmental processes in islets. Two additional controls strains were used in this study to increase the robustness of the analysis. The B6,NOD−HI20 strain (B6.g7) was chosen because it expresses the MHC-II protein I-A^q7 on a C57BL/6 background. This strain does not develop diabetes. We also used C57BL/6 mice as our most normal control strain.

Examination of the entire data set by Spearman’s rank correlation showed a low variance amongst all data (Fig. S1A, B, C). In particular the 8 wk NOD mice were grouped mainly by the age of the mice. Similarity in variance of the 6 wk samples together, and the main outlier was the 8 wk NOD (Fig. S1B). Analysis of the downregulated signature showed an enrichment of transcriptional regulatory genes (Fig. S1C). Euclidean distance and Pearson’s Correlation analysis did not provide a discernible trend in the downregulation of transcripts through the time course of NOD mice development (Fig. S1D, Data not shown).

In summary, pairwise analysis of 2 and 6 wk old NOD and NOD, Rag1−/− mice showed mostly a regulation of cell growth and development, and an inflammatory response unique to NOD. A surprising finding was the fact that as early as 6 wks of age an interferon-dependent gene signature was already found in NOD mice, but not in any of the 6 wk old controls. Many of the 6 wk inflammatory changes were evident in NOD mice as young as 4 wks, as will be detailed below.

**Principal Component Analysis Revealed that the Major Source of Transcriptional Variance between NOD and Control Mice was Immunological in Nature**

Principal component analysis (PCA) was used to evaluate the transcriptional changes responsible for the highest variance of the dataset [20]. PCA discriminated our samples by both strain and age (Fig. 2G). We extracted the top 1% of transcripts responsible for the overall PCA variance and this yielded transcripts that correlated with a progression in the age of NOD mice (Fig. S1G). Two salient features were identified by PCA and noted in Fig. 2H. The first was a group of genes selectively upregulated as early as 4 wks of age in NOD mice. These were immune response genes, including the interferon inducible genes mentioned in Fig. 2C. A second group of genes was selectively upregulated on or after 8 wks in NOD mice. This group was enriched for immune response and a variety of leukocyte specific and interferon-inducible genes. Key leukocyte cell surface markers, including Cd2, Cd3e/d/g, Cd4, Cd8a, Cd19, Cd22, T cell receptor, B cell receptor and immunologically important signaling components such as Lck, Lat, and Cd79b, were identified by PCA. Analysis by Gene Ontology and promoter scanning showed that genes identified by PCA were significantly enriched for immune response and antigen processing and presentation signatures and IRF1 was the most significant transcriptional regulator (Fig. 2I).

**Refined Staging of NOD-specific Transcriptional Changes in the Islets of Langerhans**

In order to better identify transcriptional changes positively correlated with a progression toward diabetes, we performed k-means clustering using uncentered Pearson’s correlation. Our goal was to focus on genes with a positive Pearson’s correlation throughout diabetogenesis and with lower relative expression in all our controls.

The dataset was clustered as shown in Fig. S2A. Several clusters contained groupings of genes with a positive correlation of...
expression throughout diabetogenesis. The clusters that were chosen were highlighted in red and demonstrated an increase in gene expression intensity throughout diabetogenesis, but had relatively lower expression levels in all controls. Using this analysis...
we identified 888 genes that were selected for further analysis. Pearson’s correlation excluded most of the developmental changes mentioned previously, but included immune-related changes missed by pair-wise analysis and PCA (Fig. S2C). Also, Spearman’s rank correlation analysis of the genes identified by Pearson’s showed a delineation of NOD mice at different ages (Fig. S2B).

The genes identified by Pearson’s were superimposed with pair-wise comparisons performed between 2 wk old NOD and the age in question. This allowed us to establish genes that were significantly upregulated in NOD mice of different ages. For example, there were 634 significantly upregulated genes between 2 wk and 4 wk old NOD mice (2-fold, 99% C.I.) and the intersection of these changes with Pearson’s Correlation yielded 81 significant changes at 4 wks (Fig. 3A, Table S1). These 81 genes included all 14 of the upregulated genes identified in Fig. 1A-C. The remaining genes were upregulated ≥2-fold in NOD and to a lesser extent in the controls (see below).

For subsequent time points, we combined the intersection of Pearson’s Correlation with pairwise statistics at a given age (6, 8, 12, 18, and newly diabetic), but excluded changes already significant at a previous time. Fig. 3B–C shows an example of this for 12 wk and newly diabetic changes. In the case of the 12 wk significant changes at 4 wks (Fig. 3A, Table S1). These 81 genes included 14 of the upregulated genes identified in Fig. 1A-C. The remaining genes were upregulated ≥2-fold in NOD and to a lesser extent in the controls (see below).

Detailed Analysis of Immune Signatures during T1D

To dissect the transcriptional profiles of T1D progression, we combined transcription factor binding analysis (p-scan), gene ontology, and the modules and regulators dataset of the Immunogenetics Consortium (Immgen) [15,21–24]. The idea was to add power to our approach by using groups of genes instead of analyzing any single individual transcript. Based on this approach, we parsed out the results previously shown in Fig. 3 and Table S1 as shown in Fig. 4.

At 4–6 wks of age NOD mice displayed an interferon transcriptional signature, determined by the enrichment of IRF1 and IRF2 binding sites on the promoters of upregulated genes. Cellular response to IFN-β and IFN-γ were the two most enriched GO Terms. There was also a significant but weak developmental signature (RUNX1 and Myf; Fig. 4).

Using Immgen’s modules and regulators we found 12 genes that were myeloid specific and that we termed as an “early myeloid” signature (Fig. 4B). Most of the early myeloid signature was found in all strains, but increased over time in NOD mice. The early myeloid genes were not specific for any identifiable leukocyte, but many were linked to antigen processing and presentation (H2-Aβ1, H2-Eβ1, H2-Aα4, and Cd74). This signature is compatible with an intra-islet myeloid cell previously described by our group and others [25–27].

By 8 wks of age, there was a significant upregulation in genes regulated by SPI1 (myeloid regulator) and SPIB (B lymphocyte regulator). At this time, all major leukocyte subsets implicated in the development of diabetes were represented transcriptionally. Gene ontology showed enrichment of chemotaxis and T cell activation signatures. Definitive T cell specific genes including Cd2, Cd3d, Cd5g and also a signature of T cell activation as defined by Ctl4a, Slamf1, Slamf6, Slamf7, Slf1 (Shalfen1), and Cxcr5 was defined. B cell specific genes, including the immunoglobulin and Ig-associated genes Igk, Igλ, and Cd79b were also detected (Fig. 4, Table S1). Natural killer cells were identified by the induction of genes belonging to the NK gene cluster (Kbcl, Kbd1, and Kbd17; Table S1) [28]. In 8 wk old NOD, we found 38 new myeloid transcripts, which we termed the “late myeloid” and included markers enriched on monocytes, macrophages, and dendritic cells, such as 5 members of the c-type lectin family Clec4a1, Clec4a2, Clec4a3, Clec4n, Clec12a (Fig. 4B and Table S1).

At 12 wks of age a second wave of IRF1/IRF2 response was detected. This corresponded to a GO profile that included antigen processing and presentation and positive regulation of T cell mediated cytotoxicity (Fig. 4A). At 18 wks there was further amplification of the response, increased IFNγ and IL-2 dependent gene expression, and a continued myeloid signature as evidenced by SPI1 regulated transcripts. Finally, newly diabetic mice showed an enrichment of NF-κB inducible transcripts (Fig. 4A).

Examination of transcriptional changes by Pearson’s correlation and ANOVA demonstrated that the inflammatory gene upregulation during diabetogenesis occurred in 5 major patterns. Coordinated upregulation of various transcriptional groups was found at 4, 8, and 18 wks as well as in newly diabetic mice. There was also a steady upregulation profile (Fig. S3).

Chemokines are considered the drivers of specific immune cell entry into tissues. We found 4 chemokine genes were upregulated by 4 to 6 wks: Ccl2, Ccl5, Ccl19 and Cxcl9 (Fig. 4B). Of these, Ccl5 and Cxcl9 were higher in NOD than in controls. None of the chemokine receptors for Ccl5 or Cxcl9 were detectable in 4 or 6 wks old NOD. The only chemokine receptor to be found significantly upregulated in NOD at 4 and 6 wks was Ccr2, a receptor enriched in blood monocytes but also expressed on some populations of dendritic cells. Therefore, at 4 and 6 wks there was not a detectable chemokine-chemokine receptor pairing that could be responsible for the entry of any specific leukocyte subset. However, by 8 wks of age there was NOD-specific upregulation of 11 chemokines and 7 chemokine receptors (Fig. 4B). The chemokines included ligands for recruitment of naïve (Ccl19), memory (Cxcl9/10), and activated B T cells (Cxcl9/10). We also detected at least one ligand for the recruitment of γδ T cells (Ccl22), regulatory T cells (Ccl22), B cells (Ccl13), NK cells (Ccl4, Ccl11), conventional and plasmacytoid DC (Ccl11, Ccl4), blood monocytes (Ccl2), macrophages (Ccl2, Ccl5), and neutrophils (Xcl1). Chemokine receptors for all major leukocyte populations were also found, with the exception of granulocytes. The pattern of chemokine and chemokine receptors remained mostly unchanged after 8 wks of age, except for the increase of Cxcl4 and Cxcl6 at 12–18 wks of age. The data show that at the chemokine/chemokine receptor expression level the ability to recruit all major leukocyte subsets involved in the progression of diabetes was in place by 8 wks of age.

Our approach detected 5 significantly upregulated adhesion molecules: Glycam1, Vcam1, Iam1, L1cam, and Ania1. All adhesion factors were significantly upregulated only in the NOD mice. Vcam1, Iam1 and L1cam were upregulated by 4 to 6 wks of age, Ania1 was upregulated by 8 wks of age and Glycam1 was upregulated by 12 wks of age. Glycam1 was the most upregulated adhesion factor throughout diabetogenesis. Integrins that were significantly upregulated after 12 wks of age included Igα2 (CD18), Igα1 (CD103), Iglα (CD11c), Iglα1 (CD49d), and Iglβ7. Overall the adhesion factor and integrin signature points to an enrichment of myeloid cell types. A concomitant upregulation of expression of the pan-leukocyte marker Ptpc (CD45) and modest changes in islet-specific genes were also detected (Fig. S4).

Examination of Interferon and Interferon-inducible Gene Expression by Quantitative RT-PCR

We validated 8 candidates genes that were significantly upregulated between 4 and 8 wks in our microarray data set using qRT-PCR: Cxcl9/10, Stat1, Gbp2, Iqg1, Rfp4, Gpr18, Oasl2 and
Type I interferon. Fig. 5 shows the results of the RT-PCR data (Panel A) and microarray data (Panel B) for the 8 validated targets. By RT-PCR there was significant upregulation of all 8 transcripts in 4 to 6 wk old NOD mice when compared to 2 wks. Cxcl9 and Gbp2 were significantly upregulated from 2 to 4 wks in NOD and were significantly different from all control strains at 6 wks of age (Fig. 5). As with our microarray results certain genes, like Rip3, were upregulated in NOD from 2 to 4 wks, but had comparable expression levels with controls at 6 wks of age. Both of these observations were in agreement with the microarray results and support the idea that there is an entry of leukocytes that is universal to all strains of mice and a second signature that is interferon-inducible and specific to NOD (Fig. 5B, Table S1).

We wanted to determine which interferons were transcribed in the islets of Langerhans. We reliably found a “tonic” transcript for Ifna in the islets, pancreatic lymph nodes and spleens of all strains of mice and at all time examined (Fig. 5C which only shows data from islets). There was a small level of upregulation from 2 to 4 wks in NOD mice, but expression levels were 10 to 100-fold higher than in the three control strains. Ifnb transcripts also were reliably detectable in the islets of all mice, and sporadically in the spleens and lymph nodes of NOD (Fig. 5C, data not shown). The levels of Ifnb expression did not go above the tonic expression level until 6 wk of age. At this time there were >10 fold more detectable transcripts in NOD than in C57BL/6, B6g7 or NOD.Rag1-/- mice islets. To note, pancreatic lymph nodes of NOD mice contain a detectable expression of type I interferon in plasmacytoid DC, as early as 3 wks of age [14].

In contrast to type I interferon, we did not detect tonic expression of Ifng in the spleens or lymph nodes of NOD or the control mice (Fig. 5C, and data not shown). Reliable expression of Ifng was only detected at 8 wks with maximal expression at 12 wks in NOD. This coincided with the first detectable Ifng by microarray. Based on this data, we conclude that type I interferon was expressed before Ifng during diabetogenesis. The timing of significant upregulation of Ifna and Ifnb appears to be simultaneous.

Integration with Protein-protein Interaction Networks Shows Immune Subnetworks Dominating Across Diabetes Development

We related the islet gene expression data in the context of established protein-protein interaction networks. First, we dissected the temporal changes in gene expression of our dataset by computing pairwise p values for all permutations of samples. This was done in order to identify the genes that became involved in diabetogenesis at a given age. For example, at 8 wks of age, we looked for differential expression from 2 to 6 wk NOD versus 8 to newly diabetic NOD. By this analysis, only genes that became significantly upregulated at 8 wks, but were not significant at all previous times were analyzed.

Subnetworks of genes upregulated at 6 wks contained a cluster of AP-1 related immune genes specific for myeloid lineage (Fos, Junb, Jun, Fosb, etc). The 8 wk subnetwork was strongly enriched for “Genes involved in Signaling in Immune system” (Reactome, hypergeometric p value < 10^-15) and “T Cytotoxic Cell Surface Molecules” (Biocarta, hypergeometric p value < 10^-10). The 18-wks subnetwork showed strong enrichment in members of both T-cell and B-cell receptor pathway (hypergeometric p values of 10^-6 and 10^-3, respectively; Fig. 6).

We expanded these observations by cross-referencing time point specific genes with profiles available in the Immgen database [15]. Since Immgen-derived transcriptional modules available online are defined based on the human immune cell types, we used the enrichment score strategy introduced in Benita, et. al. to compute the representation of murine immune cell types within transcriptional signatures of infiltration [29]. Consistently, the 4 wk NOD signature did not show statistically significant enrichment in immune cell types, while the 6 wk NOD signature showed non-cell type specific increase of immune cell types illustrated by hematopoietic progenitor transcriptional signatures. Strikingly, the 8, 12, 18 wk, and newly diabetic NOD mice showed a specific sequence of immune infiltration. In 8 wk NOD mice transcripts infiltration by CD8 and γδT cells was enriched (Fig. 6 and Fig. S5). This was followed by a myeloid cell re-infiltration at 12 wks, and B cell infiltration at 18 wks. Finally, newly diabetic NOD mice had strong cytotoxic helper T cell signature. This was consistent with both direct observation of islet-infiltrating cell-types and strongest interacting subnetworks identified in the data (Fig. 6, and showed that expression profiles were informative for dissecting heterogeneous cell populations.

Discussion

Several important milestones in the development of diabetes were derived from a chronological transcriptional analysis that was complemented by cytological analysis of the islets. Examination of individual genes can introduce observational bias. However the addition of Immgen, promoter scanning, ontology analysis, and modeling added an important layer of additional information. This approach allowed us to parse complex lists of genes and cells into an improved definition of the steps leading to T1D and to identify different stages in its progression. Previous microarray analyses of T1D used either accelerated methods for inducing disease or interrogated a subset of the pancreatic infiltrate[9,11–13,30]. Thus, the events leading to diabetes were temporally compressed or only a subset of the response was analyzed. Despite these limitations, important candidate markers for diabetes were identified, including genes that distinguish progressive versus non-progressive disease [30]. We have greatly expanded on our available datasets and present the first complete analysis of the entire natural diabetic program.

The time at which NOD mice become diabetic is heterogeneous and gender dependent. Despite the stochastic endpoint, the progression of the program that culminates in overt disease was...
relatively conserved and several important milestones were identified. During the first 4 wks of life, myeloid cells populated the islets, independently of diabetes susceptibility. The first major transcriptional event that differentiated the NOD from control mice was the expression of type I interferon, reliably detected by the 4th wk of age. The expression of type I interferon was correlated with a discrete appearance of CD4+ T cells inside the islets. The second milestone was the coordinated infiltration of islets by all major inflammatory cells by the 8th wk of life. This event was synchronous with markers of T cell activation and a dramatic change in islet-specific gene expression. Between the 12th and 18th wk there was further diversity in the expression of genes linked to cytotoxicity, many of which were NF-kB inducible. Despite a prolonged inflammatory infiltration starting at 8 wks, mice did not become diabetic until after 20 wks of age, indicating a partial level of control for a period of time.

The earliest expression of the autoimmune state was the type I interferon signature, its importance cannot be underestimated. It was not unexpected to find a level of constitutive type I interferon in the islets as well as in other tissues [31,32]. The key event however was the marked upregulation at 4 to 6 wks of age. Future experiments will need to address the causes and effects of the type I IFN expression. For one, we need to explain the relationship between type I IFN production and the finding of early infiltrating T cells, the specificity of which needs to be examined. Because of their striking contact with islet APC these T cells should be recognizing β-cell antigens. Surprisingly, genes linked to T cell activation were not detectable until 8 to 12 wks of age in NOD.

The type I interferon induced Cx3l9 that develops early in NOD has the ability to recruit both pathogenic and regulatory T cells that bear the Cxcr3, the receptor for Cx3l9. It is possible that the naive T cell is incapable of being diabeticogenic until it has been converted to an effector/memory phenotype at distal sites, such as the pancreatic lymph node, a site which has been shown important in diabetes development [33,34]. T cells that initiate the diabetic process may become regulated at 8 wks, but the entry of effector memory cells that are conditioned in the lymph node may cause the process to move forward starting at ~12 wks.

Concerning other stimuli, we have no evidence for viral infections in our colony, an issue that has been examined with care. But pointedly, gnotobiotic NOD mice still developed diabetes, although the microbiome did influence its development [35]. Nucleic acids have been defined as the most potent agonists of type I interferon production [36]. DNA released by apoptotic β-cells could activate nucleic acid sensor pathways for the induction of type I interferon. Inflammatory nucleic acids may result from the developmental changes that were detected during the first 4 wks. Importantly, an early apoptotic event has been discussed as a possible inductive phase of diabetes [37]. Alternatively, multiple signals may be required for the type I interferon burst which coincides with the initiation of immune infiltration. This hypothesis has been recently postulated for the induction of lupus, a type I interferon mediated autoimmunity [38]. Careful evaluation of different nucleic acid sensor pathways in NOD is lacking and is an important future direction.

Finally, we note some of the reports in the literature that reinforce the importance of a type I interferon response. Analysis of RNA isolated from whole pancreatic lymph nodes demonstrated an upregulation of type I IFN in NOD mice from 2 to 3 wks [14]. However, it is not clear if this upregulation is unique to NOD mice. Treatment of mice with type I interferon neutralizing antibodies delayed disease incidence. Higher level of Ifna expression was found in the pancreases of human TID patients with end-stage disease when compared to normal controls [39]. Diabetes prone BB rats and mice treated with streptozotocin had expression of type I interferon in their pancreatic islets [40]. There are reports of patients treated with type I interferon for chronic viral infections that then developed diabetes [41]. In the case of mice, enforced expression of type I interferon in islets caused autoimmune diabetes [42,43]. The transcription factor Ifh7, a key regulator of type I interferon upregulation, has been linked to T1D by genome-wide association studies [44]. There is an abundance of data demonstrating the importance of type I interferon in other autoimmune diseases [45].

The microarrays at 8 wks of age not only marked the detection of all major leukocyte subsets, but also showed changes in islet specific gene expression. We detected downregulation of transcription factors essential for islet development and function. Additionally, by variance analysis these arrays were more distant from all other arrays regardless of whether the genes were unfiltered, selected by PCA, or by Pearson’s correlation. We believe, as do others, that this is due to a control mechanism established in the islets that must be overcome before disease can progress [30]. Multiple genes involved in T cell regulation such as Cita4, Cd52, Hace2, Cd244, Bli-a, Cd290, and Cd274 were upregulated at 8 wks of age, indicating the potential presence of a control mechanism. By microscopy we were able to detect Foxp3+ regulatory T cells in the islets of NOD mice at 8 wks of age. The demonstration of the importance of regulation in control of disease was shown in NOD mice deficient in functional Foxp3, which developed diabetes at a faster rate than wild-type control mice [46,47]. The concept of a regulatory balance at ~8 wks has been shown by altering Treg:Teff levels using IL-2 treatment [48]. Removal of Foxp3+ Tregs in a BDC2.5 TCR transgenic model of T1D revealed an increase in Ifng signatures, which was associated with progression of disease [49].

In addition to T cell/Treg specific signatures, examination of NOD mice showed that macrophage gene expression profiles, in particular the expression of Vegf (Crig), was predictive of progression to disease [30]. The presence of a Crig+ macrophage at 10 wks was indicative of a resistance phenotype, and modulation of this population by Crig-Fc treatment protected NOD mice from becoming diabetic. It will be interesting to determine if the inflammatory changes detected between 8 and 12 wks are related to the loss of the protective macrophage signature and whether this is the final trigger that leads to overt diabetes.

Concerning Ifng, we found expression at 8 wks in NOD mice, but the maximal signal was not detected until 12 wks of age. Signaling induced by this cytokine results in different biological effects depending on the cellular targets and their activation state. In NOD protective as well as proinflammatory responses have been reported [50,51]. Whether Ifng expression in early versus late diabetogenesis results in different biological responses remains an issue for future consideration.
In sum, discrete transcriptional profiles were identified in the diabetic autoimmunity of the NOD mouse, a chronic progressive and multifactorial disease. This information may set the base to analysis and identification of causative events but also to better define gene markers that can be used to identify the stages of the human disease.

Figure 5. Quantitative RT-PCR validation of microarray data. (A) Quantitative RT-PCR was performed using SYBR green detection for the indicated genes. Bars show the mean (log2) +/− S.E.M. of at least three independent experimental replicates from 3–6 biological replicates per group. All data is represented relative to the expression of actin (∆Ct). In order to facilitate visualization on a log2 scale, values were transformed as indicated on the y-axis label. (B) Microarray results for the same genes interrogated in (A). (C) Taqman qPCR quantification of pan-IFNα, Ifnb1, or Ifng throughout diabetogenesis. Bars represent the mean of the normalized probe intensity +/− S.E.M. of 3–6 biological replicates per group. Asterisks indicate statistical significance (P < 0.05) from 2 wk NOD sample by one-tailed Mann-Whitney test. doi:10.1371/journal.pone.0059701.g005

In sum, discrete transcriptional profiles were identified in the diabetic autoimmunity of the NOD mouse, a chronic progressive and multifactorial disease. This information may set the base to analysis and identification of causative events but also to better define gene markers that can be used to identify the stages of the human disease.
Materials and Methods

Mice

NOD (NOD/ShiLtJ), NOD.Rag1$^{-/-}$ (NOD.129S7/B6-Rag1$^{tm1Mom/J}$) and B6.g7 (B6.NOD-H2g7) mouse strains were bred at Washington University School of Medicine. C57BL/6 mice were obtained from The Jackson Laboratory (Bar Harbor, ME). All of the mice used in this study were female mice. We identified the diabetic mice following two consecutive daily blood glucose readings ≥250 mg/dl. In our NOD colony, the incidence

Figure 6. Data modeling of transcriptional networks. The most significant interaction networks were calculated at (A) 6 wks (FDR 0.00006), (B) 8 wks (FDR = 0.000001) and (C) 18 wks of age (FDR = 0.00012). Interaction significance was based on the p values calculated for each age group. Notably, at 6-wk, strong developmental signature persists along with AP-1 module, generally attributed to myeloid cells. At 8-wks, strongest interacting subnetwork is T-cell specific, while 18-wk additional B-cell and cytoskeleton specific modules appear.

doi:10.1371/journal.pone.0059701.g006
of diabetes in female mice is ~90% with incidence ranging between ~20–30 wks of age. All of the 18 wk old mice had normal blood glucose for at least two days before being sampled. All mouse experiments were approved by the Division of Comparative Medicine of Washington University School of Medicine (Association for Assessment & Accreditation of Laboratory Animal Care [AAALAC] accreditation number A3301-01). Experiments were performed under institutional guidelines and all efforts were made to minimize suffering. The institutional approval number for these studies was protocol number 20110130.

Islet Isolation and Handling for Immunofluorescence

Islets were isolated with some modifications of the original protocol [52–54]. Briefly, pancreata were isolated and treated with collagenase, followed by several steps of centrifugation and washing, and finally, islets were hand-picked. Immunofluorescence analysis was performed as previously described [25]. Resident leukocytes, infiltrating leukocytes, adhesion molecules (ICAM-1 and VCAM-1), blood vessels and IgG antibody deposition in the islets were detected with the following monoclonal antibodies: anti-CD11c Alexa Fluor® 488 (clone N418), anti-CD19 phycocerythrin (PE) (clone 6D5), and anti-CD4 PE (clone RM4–5) from BioLegend, Inc., San Diego, CA, anti-CD8α PE (clone 53-6.7; BD Biosciences, San José, CA), anti-CD31 Alexa Fluor® 647 (clone 28b, kindly provided by Dr. Steven Bogen, Boston University School of Medicine, Boston, MA), and anti-mouse IgG Alexa Fluor® 488 (Invitrogen, Carlsbad, CA); Biotinylated antibodies against ICAM-1 (CD54, clone Yn1/17.4) and VCAM-1 (CD106, clone 429) were obtained from ebioscience. Streptavidin Alexa Fluor® 488 or 555 (Invitrogen) was used as the secondary reagent. Percentages of infiltrating leukocytes, adhesion molecules expression and IgG deposition were evaluated from 50 to 100 islets per mouse with groups of 4 to 6 mice per time point.

Flow Cytometry

Isolated islets were dispersed in a water bath using Cell Dissociation Solution Non-enzymatic (Sigma-Aldrich) for 15 minutes at 37°C. Islets were then pipetted several times and then passed through a pre-wet 40 μm cell strainer and washed twice in Dulbecco’s minimal essential medium with 10% fetal calf serum. Dispersed islet cells were stained with labeled antibodies against CD45 FITC (clone 30-F11), CD4 PE (clone RM4–5), CD19 PE (clone 6D5) and CD11c APC (clone N418) from BioLegend, Inc. CD8β APC (clone eBioH35-17.2) and Foxp3 (clone FJK-16s) were obtained from ebioscience. Foxp3 staining was performed following the manufacture’s protocol. Flow cytometry analysis was performed on a FACSCalibur (BD Biosciences) and data was analyzed using FlowJo software (Tree Star).

RNA Isolation

For islets of Langerhans (~100), Total RNA was isolated using the Ambion RNAqueous-Micro Kit (Life Technologies, Carlsbad, CA, USA) following the manufacturer’s instructions. For spleen and lymph nodes, RNA was isolated using Trizol (Life Technologies) following the total tissue RNA protocol. RNA was quantified by OD260 using Nanodrop (Thermo Fisher Scientific, Wilmington, DE, USA). For microarray analysis, RNA integrity and quantification was further validated using a Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).

Microarray Analysis

RNA (50 ng) was amplified using NuGEN PicoSL WTA System or NuGEN PicoPure (NuGEN, San Carlos, CA, USA) following the manufacturer’s instructions. Amplified RNA (100 ng) was labeled using Affymetrix GeneChip Whole Transcript Sense Target Labeling Assay following the manufacturer’s instructions (Affymetrix, Santa Clara, CA, USA). Labeled RNA was hybridized to Mouse Gene 1.0 ST microarrays using a GeneChip Fluidics Station 450 (Affymetrix). Microarrays were scanned using a GeneChip Scanner 3000 7G (Affymetrix). All GeneChip processing steps were performed by the Laboratory for Clinical Genomics at Washington University School of Medicine.

Initial quality control analysis of scanned microarray files was performed using Expression Console software (Affymetrix). Array data (cel files) was imported into Arraystar 5 software (DNASTar, Madison, WI, USA) and then normalized using the robust multi-array analysis method with quantile normalization [55]. Normalized data was exported as normalized linear signal intensity and then batch effect correction was performed using the Combat module of GenePattern [16,56]. The batches were as follows: 1) NOD.Rag−/− 2 wk and 6 wk, NOD 2 wk, B6;g7 6 wk, C57BL/6j 6 wk; 2) NOD 4 wk, 6 wk (arrays 4–6), and newly diabetic, 3) NOD 6 wk (arrays 1–3), 8 wk, 12 wk, and 18 wk. All raw data files (CEL) are publicly available in the Gene Expression Omnibus as accession number GSE41203.

Normalized and batch corrected data was used for all subsequent analyses.

Spearman’s Rank Correlation was calculated using GENE-E Software (Broad Institute http://www.broadinstitute.org/cancer/software/GENE-E/). Principal component analysis was performed using Population PCA software (CBDM Laboratory, Harvard University, http://cbdm.hms.harvard.edu/LabMembersPges/SD.html). For all pairwise tests contained herein, we set our threshold at two-fold change with a 99% confidence interval by moderated t test with Benjamini-Hochberg False Discovery Rate analysis [57]. Hierarchical clustering analysis and heat map plot generation was performed using Arraystar 5.

Gene Ontology analysis was performed using GeneCoDis 3.0 (http://geneodis.cnb.csic.es/analysis/; [22]). Promoter scanning analysis was performed using Psgen 159.149.109.9/psgen/; [23]) with the −950+50 settings and Jaspar mouse database. Batch name conversion was performed using the MGI Batch Query (http://www.informatics.jax.org/batch/?page=batchQF). For selecting genes specific to particular cell types we used the Immgen Modules and Regulators. The following modules were used: myeloid cells (macrophage, DC, granulocytes); coarse modules 25, 26, 48, 58, and 74, T cells: coarse module 146, B cells: coarse module 33, and NK cells: coarse module 19. Venn diagrams were generated using Arraystar 5. Pearson’s Correlation analysis was performed using Arraystar 5. Bar graphs and statistical analysis was performed using Graphpad Prism 5.0 (Graphpad Software, Inc., La Jolla, CA, USA). For selecting genes specific to particular cell types we used the Immgen Modules and Regulators. The following modules were used: myeloid cells (macrophage, DC, granulocytes); coarse modules 25, 26, 48, 58, and 74, T cells: coarse module 146, B cells: coarse module 33, and NK cells: coarse module 19. Venn diagrams were generated using Arraystar 5. Pearson’s Correlation analysis was performed using Arraystar 5. Bar graphs and statistical analysis was performed using Graphpad Prism 5.0 (Graphpad Software, Inc., La Jolla, CA, USA).
based on previous work [59]. SYBR green PCR was performed using Fast SYBR Green PCR Master Mix (Life Technologies) following the manufacturer’s instructions. TaqMan PCR was performed using TaqMan Fast Universal PCR Master Mix (Life Technologies). All qPCRs were performed on a StepOnePlus Real-Time PCR system running StepOne Software. Quality control and relative expression quantification for qPCR was performed by the StepOne software.

Network Analysis
The R package Bionet was used to identify subnetworks significantly enriched in genes differentially expressed at any given time point of diabetes development [60]. For each time point we scanned a range of false discovery rates and chose a subnetwork of 20–30 genes in size (p<0.05 by FDR).

Cell type enrichment scores were pre-computed enrichment scores for all genes based on mouse Immgen data. This included data for 193 immune cell types/subtypes and then applied a hypergeometric test to look for overrepresented set of genes. For each time point we chose a corresponding test set that consisted of the top 100 differentially expressed genes (all with p values <0.05). Equal numbers of genes were chosen for each time-point such that we could use a union of all test sets as background in hypergeometric test (Table S2).

Supporting Information
Figure S1 Summarization of microarrays data throughout analysis. (A) Summarization of all normalized and curated genes in our dataset. (B) Summarization and analysis of all genes downregulated between 2 and 6 wks in NOD and NOD.Rag2−/− mice. The Venn diagram shows all genes downregulated at least 2 fold at 99% C.I. following F.D.R. analysis. Genes downregulated in NOD are in red, genes downregulated in NOD.Rag2−/− are in green. Shared genes are in yellow. The shared group of genes were analyzed by transcription factor binding site enrichment (Pscan) or Gene Ontology enrichment (GeneCoDis). Bar graphs show the corrected p value for each type of analysis. The heat map shows the hierarchically clustered genes shared between NOD and NOD.Rag2−/−. Scale is in log2 fold change. (C) Summarization of the top 1% of variance amongst our dataset as determined by principal component analysis. For all summarization plots, we used Spearman’s rank correlation. Scales indicate the range.

Figure S2 Identification of genes positively correlated with diabetesogenesis. (A) k-means clustering analysis of 21759 normalized and curated genes in our dataset. K-means was performed using Pearson’s correlation and 50 bin size at 100 iterations. The line graphs in red represent 888 genes that had a positive correlation throughout the time course of NOD diabetes but were not upregulated from 2 wk to 6 wk in NOD.Rag2−/−. These 888 genes were plotted in the heat map to the right using hierarchical clustering (Euclidian distance). (B) Summarization of the 888 genes identified by Pearson’s correlation. Spearman’s rank correlation was used to generate the plot. Scale represents the range. (C) Venn diagrams showing the concordance of genes identified by Pearson’s correlation compared to pairwise statistical analysis (top) or principal component analysis (bottom).

Figure S3 Pearson’s correlation and ANOVA analysis demonstrate 5 main patterns of immune gene upregulation during diabetesogenesis. (Left Column) Heat maps of hierarchically clustered genes identified by Pearson’s correlation and ANOVA analysis. (Right Column) Line graphs of normalized gene expression throughout diabetesogenesis. Black line represents the normalized mean of expression for the cluster. The genes included in both columns were identical. We tested these 5 major gene sets that comprise 683 genes with significant changes across diabetes development by ANOVA. Each cluster can be associated with infiltration at distinct time points. Strikingly, three clusters were strongly enriched in specific immune cell types; first, “4 wk infiltration” cluster had overwhelming enrichment of macrophages and dendritic cell types (i.e. myeloid cells). Second was the cluster of genes that appeared at 8 wks and continued to grow on. This cluster had enrichment in T-cells, B-cells, NK cells and DC types. Finally, genes most strongly upregulated in newly diabetic NOD mice, where extraordinarily enriched in various cytotoxic T-cell types.

Figure S4 Expression levels of housekeeping, pancreas specific genes, and Pparg. Normalized expression of eight genes from pancreatic microarrays. Bars represent the log2 transformed mean+/− S.D. for 3–6 biological replicates per group.

Table S1 List of genes identified using Pearson’s correlation and pairwise statistical analysis.

Table S2 Leukocyte clusters used in the analysis.

Acknowledgments
We thank Kathy Frederick for animal husbandry and extensive technical assistance. We thank Dr. Roger Belzaire, Dr. Brian T. Edelson, and Dr. James F. Mohan for their insightful discussions and suggestions.

Author Contributions
Conceived and designed the experiments: JAC ERU. Performed the experiments: JAC BC. Analyzed the data: JAC BC FT MNA. ERU. Contributed reagents/materials/analysis tools: JAC BC FT MNA. ERU. Wrote the paper: JAC ERU.
33. Hoglund P, Mintern J, Waltzinger C, Heath W, Benoist C, et al. (1999) Immune cell transcriptome: a microarray overview. Diabetes 48: 2579-2592.

34. Gagnerault MC, Luan JJ, Lotton C, Lepault F (2002) Pancreatic islet cells are required for priming of beta cell reactive T cells in NOD mice. J Exp Med 196: 369-377.

35. Wen L, Ley RE, Volchkov PV, Stroynowsk AE, Avanesyan L, et al. (2008) Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 455: 1109-1113.

36. Gilleit M, Cao W, Yiu JY (2008) Phagocytic dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol 8: 594-606.

37. Mathis D, Vence L, Benoist C (2001) beta-Cell death during progression to diabetes. Nature 414: 792-796.

38. Baccala R, Hoebe K, Kono DH, Beutler B, Theofilopoulos AN (2007) TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med 13: 543-551.

39. Huang X, Yuan J, Goddard A, Foulis A, James RF, et al. (1995) Interferon expression in the pancreases of patients with type 1 diabetes. Diabetes 44: 658-664.

40. Huang X, Hultgren B, Dybdal N, Stesest T (1994) Ilet expression of interferon-alpha precedes diabetes in both the BB rat and streptozotocin-treated mice. Immunol 1: 469-478.

41. Fujikura T, Honda M, Yoshizaki T, Ogawa M, Matsumo H, et al. (2010) A case of type 1 diabetes onset and recurrence of Graves’ disease during peglated interferon-alpha plus rbavirin treatment for chronic hepatitis C. Intern Med 49: 1987-1990.

42. Stewart TA, Hultgren B, Huang X, Pito-Meeck S, Hully J, et al. (1993) Induction of type 1 diabetes by interferon-alpha in transgenic mice. Science 260: 1942-1946.

43. Chakrabarti D, Hultgren B, Stewart TA (1996) IFN-alpha induces autoimmune T cells through the induction of intracellular adhesion molecule-1 and B7.2. J Immunol 157: 522-528.

44. Heimig M, Petretto E, Wallace C, Bottolo L, Rotival M, et al. (2010) A transacting locus regulates an anti-viral expression network and type 1 diabetes risk. Nature 467: 460-464.

45. Theofilopoulos AN, Baccala R, Beutler B, Kono DH (2005) Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 23: 307-336.

46. Darce J, Rudra D, Li L, Nishio J, Capellotta D, et al. (2012) An N-terminal mutation of the foxp3 transcription factor alleviates arthritis but exacerbates diabetes. Diabetes 61: 731-741.

47. Bettini ML, Pan F, Bettini M, Finkelstein D, Relh JE, et al. (2012) Loss of epigenetic modification driven by the foxp3 transcription factor leads to regulatory T cell insufficiency. Immunity 36: 717-730.

48. Tang Q, Adams JY, Penaranda C, Melli K, Piaggio E, et al. (2006) Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunology 118: 689-697.

49. Feuerer M, Shen Y, Littman DR, Benoist C, Mathis D (2009) How pulpal amination of regulatory T cells unveils an autoimmune lesion within the pancreatic islets. Immunity 31: 654-664.

50. Calderon B, Suri A, Pan XO, Mills GC, Urane ER (2008) IFN-gamma-dependent regulatory circuits in immune inflammation highlighted in diabetes. J Immunol 181: 6964-6974.

51. Mor Y, Kodaka T, Kato T, Kanagawa EM, Kanagawa O (2009) Critical role of IFN-gamma in CFA-mediated protection of NOD mice from diabetes development. Immunology 129: 1291-1299.

52. Salvaglio PR, Deng S, Aryan CE, Millet I, Zavalich WS, et al. (2002) Ilet filtration: a simple and rapid new purification procedure that avoids ficoll and improves islet mass and function. Transplantation 74: 377-379.

53. Li DS, Yuan YH, Tu HJ, Liang Q, Dai LL (2004) A protocol for isletolation from mouse pancreas. Nat Protoc 4: 1699-1702.

54. Lacy PE, Kostianovsky M (1967) Method for the isolation of intact islets of Langerhans. Diabetes 16: 35-39.

55. Huang X, Yuang J, Goddard A, Foulis A, James RF, et al. (1995) Interferon gamma is sufficient to induce beta-cell destruction in NOD mice. Diabetes 44: 658-664.

56. Theofilopoulos AN, Baccala R, Beutler B, Kono DH (2005) Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 23: 307-336.

57. Darce J, Rudra D, Li L, Nishio J, Capellotta D, et al. (2012) An N-terminal mutation of the foxp3 transcription factor alleviates arthritis but exacerbates diabetes. Diabetes 61: 731-741.

58. Calderon B, Suri A, Pan XO, Mills GC, Urane ER (2008) IFN-gamma-dependent regulatory circuits in immune inflammation highlighted in diabetes. J Immunol 181: 6964-6974.

59. Mor Y, Kodaka T, Kato T, Kanagawa EM, Kanagawa O (2009) Critical role of IFN-gamma in CFA-mediated protection of NOD mice from diabetes development. Immunology 129: 1291-1299.

60. Salvaglio PR, Deng S, Aryan CE, Millet I, Zavalich WS, et al. (2002) Ilet filtration: a simple and rapid new purification procedure that avoids ficoll and improves islet mass and function. Transplantation 74: 877-879.

61. Li DS, Yuan YH, Tu HJ, Liang Q, Dai LL (2004) A protocol for isletolation from mouse pancreas. Nat Protoc 4: 1699-1702.

62. Lacy PE, Kostianovsky M (1967) Method for the isolation of intact islets of Langerhans. Diabetes 16: 35-39.

63. Inzirra RA, Bolstad BM, Collins F, Coppe LM, Hobbs B, et al. (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31: e15.

64. Johnson WE, Li C, Rabinovic A (2007) Adjusting batch effects in microarray data using empirical Bayes methods. Biostatistics 8: 116-127.

65. Ben-Zvi Y, Hochberg Y (1995) Controlling the False Discovery Rate - A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B-Methodological 57: 259-300.

66. Wang X, Seed B (2003) A PCR primer bank for quantitative gene expression analysis. Nucleic Acids Res 31: e15.

67. Stockinger S, Kastner R, Kernbauer E, Pilz A, Westermayer S, et al. (2009) Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 23: 307-336.